Novo Nordisk sues Eli Lilly over weight-loss drug claims
Danish pharmaceutical giant Novo Nordisk has launched a US lawsuit against rival Eli Lilly alleging deceptive advertising, a sign of the fierce legal and commercial battles brewing over a global weight-loss market projected to exceed $100 billion by the end of the decade.
Novo Nordisk filed a lawsuit in the US on Tuesday accusing Eli Lilly of false advertising regarding their competing weight-loss and diabetes drugs. The Danish company claims its American rival deployed nationwide campaigns to create a misleading impression that Lilly's treatments are superior.
At the heart of the dispute is how the drugs were clinically compared in public. Novo alleges Lilly compared the highest approved doses of its own medicines, Mounjaro and Zepbound, against lower, outdated doses of Novo's Ozempic and Wegovy. The Danish firm asserts the ads intentionally omitted newer, higher-dose options and buried critical clinical context to deceive consumers.
For European investors and the broader continental economy, the lawsuit highlights the escalating stakes in a sector currently dominated by Denmark's Novo Nordisk. Analysts estimate the US weight-loss drug market alone could be worth more than $100 billion by 2030. As Novo fights to protect its market share from a fast-growing competitor, this legal friction underscores the immense financial pressures driving the industry's heavyweights.
Novo is seeking a court order to force Lilly to pull the commercials and run a corrective advertising campaign. If Lilly refuses, Novo plans to file a motion for a preliminary injunction in the coming days. "Healthcare companies have a responsibility to keep their public claims accurate and current - ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns," said John F. Kuckelman, senior vice president and group general counsel for Novo Nordisk.
Eli Lilly has rejected the allegations, accusing Novo of trying to block communication of a trial it considers the gold standard. A company spokesperson said Lilly stands "firmly behind our advertising," adding: "It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available - exactly what patients deserve. We will continue to focus on the science and defend against this lawsuit vigorously."
